\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}The Genetics and Molecular Biology of Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{6}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{6}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{7}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{8}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{9}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{11}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Sequencing Technologies}{11}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{12}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{13}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{14}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{15}{subsubsection.1.1.5.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.1}Findings from Cancer Genomes}{15}{subsubsubsection.1.1.5.1.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.2}Genomic Comparisons Across Cancer Tissues}{17}{subsubsubsection.1.1.5.1.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.3}Cancer Genomic Data Resources}{18}{subsubsubsection.1.1.5.1.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{18}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{18}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{19}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{20}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{21}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{21}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{22}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{24}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{25}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{26}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{26}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{28}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{28}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{29}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{30}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{30}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{33}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{35}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{38}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{38}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{39}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{42}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{43}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{44}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{47}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{48}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{48}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{49}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{49}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{49}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{50}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{50}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{50}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{51}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{52}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{52}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occurring Mutations}{53}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{53}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{54}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{58}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{58}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{58}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{59}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{60}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{61}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{61}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{61}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{63}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{63}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{64}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{64}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{65}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{66}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{66}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{66}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{67}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{68}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{69}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{69}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{70}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{70}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{70}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{71}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{71}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{73}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{75}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{77}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{77}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{80}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{80}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{85}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{87}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{87}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{91}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{93}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{101}{subsubsection.3.3.2.2}
\contentsline {subsubsubsection}{\numberline {3.3.2.2.1}Importance of Directional Testing}{101}{subsubsubsection.3.3.2.2.1}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{103}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{103}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{104}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Hierarchy Based on Biological Context}{105}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{106}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{110}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{110}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{111}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{113}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{113}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{113}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{114}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{114}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{115}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{116}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{117}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{119}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{120}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{124}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{126}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with siRNA screen candidates}{126}{subsection.4.2.1}
\contentsline {subsubsection}{\numberline {4.2.1.1}Comparison with correlation}{127}{subsubsection.4.2.1.1}
\contentsline {subsubsection}{\numberline {4.2.1.2}Comparison with viability}{129}{subsubsection.4.2.1.2}
\contentsline {subsubsection}{\numberline {4.2.1.3}Comparison with secondary siRNA screen candidates}{131}{subsubsection.4.2.1.3}
\contentsline {subsubsection}{\numberline {4.2.1.4}Comparison of screen at pathway level}{132}{subsubsection.4.2.1.4}
\contentsline {subsubsubsection}{\numberline {4.2.1.4.1}Resampling of genes for pathway enrichment}{134}{subsubsubsection.4.2.1.4.1}
\contentsline {section}{\numberline {4.3}Metagene Analysis}{140}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Pathway expression}{140}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Somatic mutation}{142}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Mutation locus}{144}{subsection.4.3.3}
\contentsline {subsection}{\numberline {4.3.4}Synthetic lethal metagenes}{146}{subsection.4.3.4}
\contentsline {section}{\numberline {4.4}Replication in stomach cancer}{147}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Synthetic Lethal Genes and Pathways}{148}{subsection.4.4.1}
\contentsline {subsection}{\numberline {4.4.2}Synthetic Lethal Expression Profiles}{149}{subsection.4.4.2}
\contentsline {subsection}{\numberline {4.4.3}Comparison to Primary Screen}{152}{subsection.4.4.3}
\contentsline {subsubsection}{\numberline {4.4.3.1}Resampling Analysis}{153}{subsubsection.4.4.3.1}
\contentsline {subsection}{\numberline {4.4.4}Metagene Analysis}{153}{subsection.4.4.4}
\contentsline {section}{\numberline {4.5}Global Synthetic Lethality}{154}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Hub Genes}{155}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Hub Pathways}{157}{subsection.4.5.2}
\contentsline {section}{\numberline {4.6}Replication in cell line encyclopaedia}{158}{section.4.6}
\contentsline {section}{\numberline {4.7}Discussion}{160}{section.4.7}
\contentsline {subsection}{\numberline {4.7.1}Strengths of the SLIPT Methodology}{160}{subsection.4.7.1}
\contentsline {subsection}{\numberline {4.7.2}Syntheic Lethal Pathways for E-cadherin}{161}{subsection.4.7.2}
\contentsline {subsection}{\numberline {4.7.3}Replication and Validation}{163}{subsection.4.7.3}
\contentsline {subsubsection}{\numberline {4.7.3.1}Integration with siRNA Screening}{163}{subsubsection.4.7.3.1}
\contentsline {subsubsection}{\numberline {4.7.3.2}Replication across Tissues and Cell lines}{164}{subsubsection.4.7.3.2}
\contentsline {section}{\numberline {4.8}Summary}{165}{section.4.8}
\contentsline {paragraph}{Aims}{167}{section*.8}
\contentsline {paragraph}{Summary}{167}{section*.9}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{168}{chapter.5}
\contentsline {section}{\numberline {5.1}Synthetic Lethal Genes in Reactome Pathways}{169}{section.5.1}
\contentsline {subsection}{\numberline {5.1.1}The PI3K/AKT Pathway}{169}{subsection.5.1.1}
\contentsline {subsection}{\numberline {5.1.2}The Extracellular Matrix}{171}{subsection.5.1.2}
\contentsline {subsection}{\numberline {5.1.3}G Protein Coupled Receptors}{174}{subsection.5.1.3}
\contentsline {subsection}{\numberline {5.1.4}Gene Regulation and Translation}{174}{subsection.5.1.4}
\contentsline {section}{\numberline {5.2}Network Analysis of Synthetic Lethal Genes}{175}{section.5.2}
\contentsline {subsection}{\numberline {5.2.1}Gene Connectivity and Vertex Degree}{175}{subsection.5.2.1}
\contentsline {subsection}{\numberline {5.2.2}Gene Importance and Centrality}{177}{subsection.5.2.2}
\contentsline {subsubsection}{\numberline {5.2.2.1}Information Centrality}{177}{subsubsection.5.2.2.1}
\contentsline {subsubsection}{\numberline {5.2.2.2}PageRank Centrality}{179}{subsubsection.5.2.2.2}
\contentsline {section}{\numberline {5.3}Testing Pathway Structure of Synthetic Lethal Genes}{181}{section.5.3}
\contentsline {subsection}{\numberline {5.3.1}Hierarchical Pathway Structure}{181}{subsection.5.3.1}
\contentsline {subsubsection}{\numberline {5.3.1.1}Contextual Hierarchy of PI3K}{181}{subsubsection.5.3.1.1}
\contentsline {subsubsection}{\numberline {5.3.1.2}Testing Contextual Hierarchy of Synthetic Lethal Genes}{181}{subsubsection.5.3.1.2}
\contentsline {subsection}{\numberline {5.3.2}Upstream or Downstream Synthetic Lethality}{184}{subsection.5.3.2}
\contentsline {subsubsection}{\numberline {5.3.2.1}Measuring Structure of Candidates within PI3K}{185}{subsubsection.5.3.2.1}
\contentsline {subsubsection}{\numberline {5.3.2.2}Resampling for Synthetic Lethal Pathway Structure}{187}{subsubsection.5.3.2.2}
\contentsline {section}{\numberline {5.4}Discussion}{188}{section.5.4}
\contentsline {section}{\numberline {5.5}Summary}{190}{section.5.5}
\contentsline {paragraph}{Aims}{191}{section*.10}
\contentsline {paragraph}{Summary}{191}{section*.11}
\contentsline {chapter}{\numberline {6}Simulation and Modeling of Synthetic Lethal Pathways}{192}{chapter.6}
\contentsline {section}{\numberline {6.1}Comparing methods}{193}{section.6.1}
\contentsline {subsection}{\numberline {6.1.1}Performance of SLIPT and $\chi ^2$ across Quantiles}{193}{subsection.6.1.1}
\contentsline {subsubsection}{\numberline {6.1.1.1}Correlated Query Genes affects Specificity}{193}{subsubsection.6.1.1.1}
\contentsline {subsection}{\numberline {6.1.2}Correlation as a Synthetic Lethal Detection Strategy}{193}{subsection.6.1.2}
\contentsline {subsection}{\numberline {6.1.3}Testing for Bimodality with BiSEp}{193}{subsection.6.1.3}
\contentsline {subsection}{\numberline {6.1.4}Testing Synthetic Lethal Genes with Linear Models}{193}{subsection.6.1.4}
\contentsline {section}{\numberline {6.2}Simulations with Graph Structures}{193}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance over a Graph Structure}{194}{subsection.6.2.1}
\contentsline {subsection}{\numberline {6.2.2}Performance with Inhibitions}{199}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Synthetic Lethality across Graph Structures}{204}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance with feasible gene numbers (20,000)}{208}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations over pathway-based graphs}{217}{section.6.3}
\contentsline {section}{\numberline {6.4}Discussion}{220}{section.6.4}
\contentsline {section}{\numberline {6.5}Summary}{221}{section.6.5}
\contentsline {paragraph}{Aims}{222}{section*.4}
\contentsline {paragraph}{Summary}{222}{section*.5}
\contentsline {chapter}{\numberline {7}Discussion}{258}{chapter.7}
\contentsline {paragraph}{Aims}{258}{section*.14}
\contentsline {paragraph}{Summary}{258}{section*.15}
\contentsline {section}{\numberline {7.1}Significance}{260}{section.7.1}
\contentsline {section}{\numberline {7.2}Future Directions}{261}{section.7.2}
\contentsline {section}{\numberline {7.3}Conclusion}{262}{section.7.3}
\contentsline {chapter}{\numberline {8}Conclusion}{264}{chapter.8}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{265}{section*.5}
\contentsline {chapter}{\numberline {A}Sample Quality}{291}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{291}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{294}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{298}{appendix.B}
\contentsline {chapter}{\numberline {C}Secondary Screen Data}{307}{appendix.C}
\contentsline {chapter}{\numberline {D}Mutation Analysis in Breast Cancer}{309}{appendix.D}
\contentsline {section}{\numberline {D.1}Synthetic Lethal Genes and Pathways}{309}{section.D.1}
\contentsline {section}{\numberline {D.2}Synthetic Lethal Expression Profiles}{312}{section.D.2}
\contentsline {section}{\numberline {D.3}Comparison to Primary Screen}{315}{section.D.3}
\contentsline {subsection}{\numberline {D.3.1}Resampling Analysis}{317}{subsection.D.3.1}
\contentsline {section}{\numberline {D.4}Compare SLIPT genes}{319}{section.D.4}
\contentsline {section}{\numberline {D.5}Metagene Analysis}{322}{section.D.5}
\contentsline {section}{\numberline {D.6}Mutation Variation}{323}{section.D.6}
\contentsline {subsection}{\numberline {D.6.1}Mutation Frequency}{323}{subsection.D.6.1}
\contentsline {subsection}{\numberline {D.6.2}PI3K Mutation Expression}{325}{subsection.D.6.2}
\contentsline {chapter}{\numberline {E}Metagene Expression Profiles}{328}{appendix.E}
\contentsline {chapter}{\numberline {F}Stomach Expression Analysis}{334}{appendix.F}
\contentsline {section}{\numberline {F.1}Synthetic Lethal Genes and Pathways}{334}{section.F.1}
\contentsline {section}{\numberline {F.2}Comparison to Primary Screen}{337}{section.F.2}
\contentsline {subsection}{\numberline {F.2.1}Resampling Analysis}{339}{subsection.F.2.1}
\contentsline {section}{\numberline {F.3}Metagene Analysis}{341}{section.F.3}
\contentsline {chapter}{\numberline {G}Stomach Mutation Analysis}{342}{appendix.G}
\contentsline {section}{\numberline {G.1}Synthetic Lethal Genes and Pathways}{342}{section.G.1}
\contentsline {section}{\numberline {G.2}Synthetic Lethal Expression Profiles}{345}{section.G.2}
\contentsline {section}{\numberline {G.3}Comparison to Primary Screen}{348}{section.G.3}
\contentsline {subsection}{\numberline {G.3.1}Resampling Analysis}{350}{subsection.G.3.1}
\contentsline {section}{\numberline {G.4}Metagene Analysis}{352}{section.G.4}
\contentsline {chapter}{\numberline {H}Global Synthetic Lethality in Stomach Cancer}{353}{appendix.H}
\contentsline {section}{\numberline {H.1}Hub Genes}{355}{section.H.1}
\contentsline {section}{\numberline {H.2}Hub Pathways}{356}{section.H.2}
\contentsline {chapter}{\numberline {I}Replication in cell line encyclopaedia}{357}{appendix.I}
\contentsline {chapter}{\numberline {J}Synthetic Lethal Genes in Pathways}{363}{appendix.J}
\contentsline {chapter}{\numberline {K}Pathway Connectivity for Mutation SLIPT}{371}{appendix.K}
\contentsline {chapter}{\numberline {L}Information Centrality for Gene Essentiality}{375}{appendix.L}
\contentsline {chapter}{\numberline {M}Pathway Structure for Mutation SLIPT}{378}{appendix.M}
\contentsline {chapter}{\numberline {N}Graph Structures}{382}{appendix.N}
\contentsline {chapter}{\numberline {O}Graph Simulations}{392}{appendix.O}
\contentsline {chapter}{\numberline {P}Graph Simulations with Inhibition}{397}{appendix.P}
\contentsline {chapter}{\numberline {Q}Graph Simulations 20K genes}{407}{appendix.Q}
\contentsline {chapter}{\numberline {R}Graph Simulations 20K genes with Inhibition}{412}{appendix.R}
\contentsline {chapter}{\numberline {S}Pathway Simulations}{422}{appendix.S}
